Article
Development of quantitative molecular clinical end points for siRNA clinical trials.
The Journal of investigative dermatology - 1 May 2011
Hickerson Robyn P, Leachman Sancy A, Pho Lana N, Gonzalez-Gonzalez Emilio, Smith Frances J D, McLean W H Irwin, Contag Christopher H, Leake Devin, Milstone Leonard M, Kaspar Roger L
Abstract excerpt
RNA interference (RNAi) is an evolutionarily conserved mechanism that results in specific gene inhibition at the mRNA level. The discovery that short interfering RNAs (siRNAs) are selective, potent, and can largely avoid immune surveillance has resulted in keen interest to develop these inhibitors as therapeutics. A single nucleotide-specific siRNA (K6a_513a.12, also known as TD101) was recently evaluated in a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.